

Curriculum Vitae and Publications

Pierosandro Tagliaferri, MD

BIOGRAPHICAL SKETCHES

Born in [REDACTED]

Marital Status: [REDACTED]

Working Address: Edificio Clinico IX Livello, Università Magna Græcia di Catanzaro, Campus "Salvatore Venuta" Germaneto 88100 Catanzaro Italy

Phone 0039 0961 369 4324

e-mail tagliaferri@unicz.it

EDUCATION

1975 High School Degree Liceo-Ginnasio Statale J. Sannazzaro, Naples, Italy

1981 Medical Degree Medical School "Federico II" University of Naples, Italy

1984 Oncology Specialty Medical School University of Bari, Italy

WORKING EXPERIENCES

1983 Guest Researcher, Laboratory of Experimental Pathology, National Cancer Institute-FCRF, National Institutes of Health, Frederick, MD, USA (Sponsor Dr. Umberto Saffiotti)

1983-1984 Guest Researcher International Institute of Genetic and Biophysics, National Council of Researches, Naples, Italy (Supervisor Prof. F. Blasi)

1984 – 1987 Fogarty Visiting Fellow, Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. (supervisors Yoon Sang Cho-Chung MD, PhD, Robert H Bassin Ph.D)

1987-1988 Fellow Associazione Italiana per la Ricerca sul Cancro (A.I.R.C.), Medical Oncology Unit, "Federico II" University of Naples Italy

1988- 1998 Assistant Professor, Chair of Medical Oncology– Medical School "Federico II" University of Naples Clinical staff Medical Oncology Medical Oncology Unit AO Policlinico (Dir Prof AR Bianco)

1998-2007 Tenure Associate Professor of Medical Oncology (MED/06) Medical School "Magna Græcia" University of Catanzaro, Italy

PRESENT POSITION

**From 2006 Tenure Full professor (MED/06) - Medical School "Magna Graecia"
University of Catanzaro, Italy**

**From 2007 to 2014 Director Medical Oncology Division – "Tommaso Campanella
Cancer Center" Catanzar, Italy**

**From 2007 Director Post Graduate School in Medical Oncology and is part of the
Professor Board of the International PhD program in experimental oncology at the
Magna Graecia University of Catanzaro**

**From 2015 Director Medical Oncology Division –A.O.U. "Mater Domini"
Catanzaro, Italy**

SCIENTIFICS BOARDS

**Prof. Tagliaferri. is active member of the Associazione Italiana di Oncologia
Medica (AIOM) (2011-2015)**

PATENTS


1. **Three Dimentional polymeric scaffold** (for in vivo recapitulation of the human bone marrow microenvironment) – P.N. RM2012A00454 on 17.08.2011
2. **SNALPS formulation for entrapment of miR-34a for the treatment of multiple myeloma** – P:N: FI2012A000025 on 14.02.2012
3. **miR-221/222 inhibitors for the treatment of multiple myeloma** – PCT n. MBW12999-2013
4. **PEGylated Aqueous core PLA-nanocapsules as efficacious gene delivery vehicle** (RE: MB113350-IT) deposit in progress September 2013
5. **Inibitori del cluster Mir-17-92 per l'attività anti-tumorale nel mieloma multiplo e in altri tumori** (RM2014A000712 on il 09.12.2014)

Experience in GCP trials as PI

GCP training (Course completion date: 19 July 2019)

**I authorize the processing of personal data, in accordance with the provisions of Law 196/03 and
GDPR 679/2016**

Prof. Pierosandro Tagliaferri

A large black rectangular redaction box covering the signature of Prof. Pierosandro Tagliaferri.

Catanzaro March 26 2020

Publication

1. Amodio N, Rossi M, Raimondi L, Pitari MR, Botta C, Tagliaferri P, Tassone P. miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies. *Oncotarget*. 2015 May 30;6(15):12837-12861. Review.
2. Di Martino MT, Amodio N, Tassone P, Tagliaferri P. Functional Analysis of microRNA in Multiple Myeloma. *Methods Mol Biol*. 2015 May 14.
3. Morelli E, Leone E, Cantafio ME, Di Martino MT, Amodio N, Biamonte L, Gullà A, Foresta U, Rita Pitari M, Botta C, Rossi M, Neri A, Munshi NC, Anderson KC, Tagliaferri P, Tassone P. Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo. *Leukemia*. 2015 May 19. doi: 10.1038/leu.2015.124.
4. Cusi MG, Botta C, Pastina P, Rossetti MG, Dreassi E, Guidelli GM, Fioravanti A, Martino EC, Gandolfo C, Pagliuchi M, Basile A, Carbone SF, Ricci V, Micheli L, Tassone P, Tagliaferri P, Pirtoli L, Correale P. Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients. *Cancer Immunol Immunother*. 2015 Jun 2.
5. Di Martino MT, Guzzi PH, Caracciolo D, Agnelli L, Neri A, Walker BA, Morgan GJ, Cannataro M, Tassone P, Tagliaferri P. Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma. *Oncotarget*. 2015 May 27.
6. Ciliberto D, Staropoli N, Caglioti F, Gualtieri S, Fiorillo L, Chiellino S, De Angelis AM, Mendicino F, Botta C, Caraglia M, Tassone P, Tagliaferri P. A systemic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? *Cancer Biol Ther*. 2015 Jun 10:0.
7. Botta C, Gullà A, Correale P, Tagliaferri P, Tassone P. Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities. *Front Oncol*. 2014 Dec 8;4:348. doi: 10.3389/fonc.2014.00348. eCollection 2014. Review.
8. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014 Investigators. First-line crizotinib versus

- chemotherapy in ALK-positive lung cancer. *N Engl J Med.* 2014 Dec 4;371(23):2167-77.
9. Misso G, Di Martino MT, De Rosa G, Farooqi AA, Lombardi A, Campani V, Zarone MR, Gullà A, Tagliaferri P, Tassone P, Caraglia M. Mir-34: a new weapon against cancer? *Mol Ther Nucleic Acids.* 2014 Sep 23;3:e194. doi: 10.1038/mtna.2014.47. Review.
 10. Raimondi L, Amodio N, Di Martino MT, Altomare E, Leotta M, Caracciolo D, Gullà A, Neri A, Taverna S, D'Aquila P, Alessandro R, Giordano A, Tagliaferri P, Tassone P. Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity. *Oncotarget.* 2014 May 30;5(10):3039-54.
 11. Leotta M, Biamonte L, Raimondi L, Ronchetti D, Di Martino MT, Botta C, Leone E, Pitari MR, Neri A, Giordano A, Tagliaferri P, Tassone P, Amodio N. A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells. *J Cell Physiol.* 2014 Dec;229(12):2106-16. doi: 10.1002/jcp.24669.
 12. Staropoli N, Ciliberto D, Botta C, Fiorillo L, Grimaldi A, Lama S, Caraglia M, Salvino A, Tassone P, Tagliaferri P. Pegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trials. *Cancer Biol Ther.* 2014 Jun 1;15(6):707-20. doi: 10.4161/cbt.28557. Epub 2014 Mar 21. Review.
 13. Marvaso G, Barone A, Amodio N, Raimondi L, Agosti V, Altomare E, Scotti V, Lombardi A, Bianco R, Bianco C, Caraglia M, Tassone P, Tagliaferri P. Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro. *Cancer Biol Ther.* 2014 Jun 1;15(6):797-805. doi: 10.4161/cbt.28556. Epub 2014 Mar 21.
 14. Rossi M, Gentile M, Toscano R, Recchia AG, Bossio S, Caruso N, De Stefano L, Granata T, Pellicanò M, Vigna E, Tagliaferri P, Tassone P, Morabito F. Enumeration of interleukin-10-positive B cells from peripheral blood of patients with chronic lymphocytic leukemia. *Leuk Lymphoma.* 2014 Jun;55(6):1394-6. doi: 10.3109/10428194.2013.824078.
 15. Scognamiglio I, Di Martino MT, Campani V, Virgilio A, Galeone A, Gullà A, Gallo Cantafio ME, Misso G, Tagliaferri P, Tassone P, Caraglia M, De Rosa G. Transferrin-Conjugated SNALPs Encapsulating 2'-O-Methylated miR-34a for the Treatment of Multiple Myeloma. *Biomed Res Int.* 2014;2014:217365. doi: 10.1155/2014/217365. Epub 2014 Feb 13. PubMed PMID: 24683542; PubMed Central PMCID: PMC3943297.

- 16.** Staropoli N, Ciliberto D, Botta C, Fiorillo L, Grimaldi A, Lama S, Caraglia M, Salvino A, Tassone P, Tagliaferri P. Pegylated liposomal doxorubicin in the management of ovarian cancer: A systematic review and metaanalysis of randomized trials. *Cancer Biol Ther.* 2014 Mar 21;15(6). [Epub ahead of print] PubMed PMID: 24658024.
- 17.** Marvaso G, Barone A, Amodio N, Raimondi L, Agosti V, Altomare E, Scotti V, Lombardi A, Bianco R, Bianco C, Caraglia M, Tassone P, Tagliaferri P. Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro. *Cancer Biol Ther.* 2014 Mar 21;15(6). [Epub ahead of print] PubMed PMID: 24657936.
- 18.** Di Martino MT, Campani V, Misso G, Gallo Cantafio ME, Gullà A, Foresta U, Guzzi PH, Castellano M, Grimaldi A, Gigantino V, Franco R, Lusa S, Cannataro M, Tagliaferri P, De Rosa G, Tassone P, Caraglia M. In Vivo Activity of MiR-34^o Mimics Delivered by Stable Nucleic Acid Lipid Particles (SNALPs) against Multiple Myeloma. *PLoS One.* 2014 Feb 27;9(2):e90005. doi: 10.1371/journal.pone.0090005. eCollection 2014. PubMed PMID: 24587182; PubMed Central PMCID: PMC3937395.
- 19.** Amodio N, Bellizzi D, Leotta M, Raimondi L, Biamonte L, D'Aquila P, Di Martino MT, Calimeri T, Rossi M, Lionetti M, Leone E, Passarino G, Neri A, Giordano A, Tagliaferri P, Tassone P. miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. *Cell Cycle.* 2013 Sep 25;12(23). [Epub ahead of print] PubMed PMID: 24091729.
- 20.** Rossi M, Gentile M, Toscano R, Recchia AG, Bossio S, Caruso N, De Stefano L, Granata T, Pellicanò M, Vigna E, Tagliaferri P, Tassone P, Morabito F. Enumeration of IL-10-positive B cells from peripheral blood of Chronic Lymphocytic Leukemia patients. *Leuk Lymphoma.* 2013 Sep 2. [Epub ahead of print] PubMed PMID: 23998252.
- 21.** Rossi M, Amodio N, Di Martino MT, Caracciolo D, Tagliaferri P, Tassone P. Fromtarget therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario. *Curr Drug Targets.* 2013 Sep;14(10):1144-9. PubMed PMID: 23834146.
- 22.** Botta C, Barbieri V, Ciliberto D, Rossi A, Rocco D, Addeo R, Staropoli N, Pastina P, Marvaso G, Martellucci I, Guglielmo A, Pirtoli L, Sperlongano P, Gridelli C, Caraglia M, Tassone P, Tagliaferri P, Correale P. Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. *Cancer Biol Ther.* 2013 Jun;14(6):469-75. doi: 10.4161/cbt.24425. PubMed PMID: 23760488; PubMed Central PMCID: PMC3813562.

23. Misso G, Zappavigna S, Castellano M, De Rosa G, Di Martino MT, Tagliaferri P, Tassone P, Caraglia M. Emerging pathways as individualized therapeutic target of multiple myeloma. *Expert Opin Biol Ther.* 2013 Jun;13 Suppl 1:S95-109. doi: 10.1517/14712598.2013.807338. Epub 2013 Jun 6. PubMed PMID: 23738692.
24. Cucinotto I, Fiorillo L, Gualtieri S, Arbitrio M, Ciliberto D, Staropoli N, Grimaldi A, Luce A, Tassone P, Caraglia M, Tagliaferri P. Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time? *J Drug Deliv.* 2013;2013:905091. doi: 10.1155/2013/905091. Epub 2013 May 2. PubMed PMID: 23738077; PubMed Central PMCID: PMC3659516.
25. Rossi M, Botta C, Correale P, Tassone P, Tagliaferri P. Immunologic microenvironment and personalized treatment in multiple myeloma. *Expert Opin Biol Ther.* 2013 Jun;13 Suppl 1:S83-93. doi: 10.1517/14712598.2013.799130. Epub 2013 May 22. PubMed PMID: 23692463.
26. Amodio N, Di Martino MT, Neri A, Tagliaferri P, Tassone P. Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma. *Expert Opin Biol Ther.* 2013 Jun;13 Suppl 1:S125-37. doi: 10.1517/14712598.2013.796356. Epub 2013 May 22.
27. Gori S, Di Maio M, Pinto C, Alabiso O, Baldini E, Barbato E, Beretta GD, Bravi S, Caffo O, Canobbio L, Carozza F, Cinieri S, Cruciani G, Dinota A, Gebbia V, Giustini L, Graiff C, Molino A, Muggiano A, Pandoli G, Puglisi F, Tagliaferri P, Tomao S, Lunardi G, Venturini M; AIOM Working Group "Interaction with Regional Sections" (2009-2011). Impact of use of oral anticancer drugs on activity of Italian oncology practices: results of a survey conducted by the Italian Society of Medical Oncology (AIOM). *Tumori.* 2013 Jan-Feb;99(1):35-8. doi: 10.1700/1248.13785. PubMed PMID: 23548997.
28. Di Martino MT, Gullà A, Cantafio ME, Lionetti M, Leone E, Amodio N, Guzzi PH, Foresta U, Conforti F, Cannataro M, Neri A, Giordano A, Tagliaferri P, Tassone P. In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. *Oncotarget.* 2013 Feb;4(2):242-55. PubMed PMID: 23479461.
29. Leone E, Morelli E, Di Martino MT, Amodio N, Foresta U, Gullà A, Rossi M, Neri A, Giordano A, Munshi NC, Anderson KC, Tagliaferri P, Tassone P. Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. *Clin Cancer Res.* 2013 Apr 15;19(8):2096-106. doi: 10.1158/1078-0432.CCR-12-3325. Epub 2013 Feb 27.

30. Staropoli N, Ciliberto D, Botta C, Fiorillo L, Gualtieri S, Salvino A, Tassone P, Tagliaferri P. A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it? *J Ovarian Res.* 2013 Feb 6;6(1):10. doi: 10.1186/1757-2215-6-10.
31. Rossi M, Pitari MR, Amodio N, Di Martino MT, Conforti F, Leone E, Botta C, Paolino FM, Del Giudice T, Iuliano E, Caraglia M, Ferrarini M, Giordano A, Tagliaferri P, Tassone P. miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease. *J Cell Physiol.* 2013 Jul;228(7):1506-15. doi: 10.1002/jcp.24306.
32. Amodio N, Di Martino MT, Foresta U, Leone E, Lionetti M, Leotta M, Gullà AM, Pitari MR, Conforti F, Rossi M, Agosti V, Fulciniti M, Misso G, Morabito F, Ferrarini M, Neri A, Caraglia M, Munshi NC, Anderson KC, Tagliaferri P, Tassone P. miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. *Cell Death Dis.* 2012 Nov 29;3:e436. doi: 10.1038/cddis.2012.175.
33. Amodio N, Leotta M, Bellizzi D, Di Martino MT, D'Aquila P, Lionetti M, Fabiani F, Leone E, Gullà AM, Passarino G, Caraglia M, Negrini M, Neri A, Giordano A, Tagliaferri P, Tassone P. DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. *Oncotarget.* 2012 Oct;3(10):1246-58.
34. Guzzi PH, Agapito G, Di Martino MT, Arbitrio M, Tassone P, Tagliaferri P, Cannataro M. DMET-analyzer: automatic analysis of Affymetrix DMET data. *BMC Bioinformatics.* 2012 Oct 5;13:258. doi: 10.1186/1471-2105-13-258.
35. Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, Pitari MR, Cantafio ME, Gullà A, Conforti F, Morelli E, Tomaino V, Rossi M, Negrini M, Ferrarini M, Caraglia M, Shammas MA, Munshi NC, Anderson KC, Neri A, Tagliaferri P, Tassone P. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. *Clin Cancer Res.* 2012 Nov 15;18(22):6260-70. doi: 10.1158/1078-0432.CCR-12-1708. Epub 2012 Oct 3.
36. Caraglia M, Dicitore A, Marra M, Castiglioni S, Persani L, Sperlongano P, Tagliaferri P, Abbruzzese A, Vitale G. Type I interferons: ancient peptides with still under-discovered anti-cancer properties. *Protein Pept Lett.* 2013 Apr;20(4):412-23. Review.
37. Ciliberto D, Botta C, Correale P, Rossi M, Caraglia M, Tassone P, Tagliaferri P. Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials. *Eur J*

Cancer. 2013 Feb;49(3):593-603. doi: 10.1016/j.ejca.2012.08.019. Epub 2012 Sep 16.

38. Tassone P, Tagliaferri P. Editorial: New approaches in the treatment of multiple myeloma: from target-based agents to the new era of microRNAs (dedicated to the memory of Prof. Salvatore Venuta). *Curr Cancer Drug Targets*. 2012 Sep;12(7):741-2..
39. Blotta S, Jakubikova J, Calimeri T, Roccaro AM, Amodio N, Azab AK, Foresta U, Mitsiades CS, Rossi M, Todoerti K, Molica S, Morabito F, Neri A, Tagliaferri P, Tassone P, Anderson KC, Munshi NC. Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma. *Blood*. 2012 Dec 13;120(25):5002-13. doi: 10.1182/blood-2011-07-368142. Epub 2012 Jul 20. PubMed PMID: 22821765.
40. Correale P, Rotundo MS, Botta C, Del Vecchio MT, Tassone P, Tagliaferri P. Tumor infiltration by chemokine receptor 7 (CCR7)(+) T-lymphocytes is a favorable prognostic factor in metastatic colorectal cancer. *Oncoimmunology*. 2012 Jul 1;1(4):531-532. PubMed PMID: 22754775;
41. Tassone P, Neri P, Burger R, Di Martino MT, Leone E, Amodio N, Caraglia M, Tagliaferri P. Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma. *Curr Cancer Drug Targets*. 2012 Sep;12(7):814-22. Review.
42. Tagliaferri P, Rossi M, Di Martino MT, Amodio N, Leone E, Gulla A, Neri A, Tassone P. Promises and challenges of MicroRNA-based treatment of multiple myeloma. *Curr Cancer Drug Targets*. 2012 Sep;12(7):838-46. Review.
43. Botta C, Bestoso E, Apollinari S, Cusi MG, Pastina P, Abbruzzese A, Sperlongano P, Misso G, Caraglia M, Tassone P, Tagliaferri P, Correale P. Immune-modulating Effects of the Newest Cetuximab-based Chemoimmunotherapy Regimen in Advanced Colorectal Cancer Patients. *J Immunother*. 2012 Jun;35(5):440-7
44. Ciliberto D, Prati U, Roveda L, Barbieri V, Staropoli N, Abbruzzese A, Caraglia M, Di Maio M, Flotta D, Tassone P, Tagliaferri P. Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trials. *Oncol Rep*. 2012 Jun;27(6):1849-56. doi: 10.3892/or.2012.1740
45. Misso G, Giuberti G, Lombardi A, Grimaldi A, Ricciardiello F, Giordano A, Tagliaferri P, Abbruzzese A, Caraglia M. Pharmacological inhibition of HSP90 and ras activity as a new strategy in the treatment of HNSCC. *J Cell Physiol*. 2012 May 7. doi: 10.1002/jcp.24112

46. Correale P, Rotundo MS, Botta C, Del Vecchio MT, Ginanneschi C, Licchetta A, Conca R, Apollinari S, De Luca F, Tassone P, Tagliaferri P. Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma. *Clin Cancer Res.* 2012 Feb 1;18(3):850-7. Epub 2011 Dec 5
47. Gori S, Di Maio M, Pinto C, Alabiso O, Baldini E, Barbato E, Beretta GD, Bravi S, Caffo O, Canobbio L, Carrozza F, Cinieri S, Cruciani G, Dinota A, Gebbia V, Giustini L, Graiff C, Molino A, Muggiano A, Pandoli G, Puglisi F, Tagliaferri P, Tomao S, Venturini M. Disparity in the "time to patient access" to new anti-cancer drugs in Italian regions. Results of a survey conducted by the Italian Society of Medical Oncology (AIOM). *Tumori.* 2011 Jul-Aug;97(4):442-8. doi: 10.1700/950.10395.
48. Di Martino MT, Arbitrio M, Leone E, Guzzi PH, Saveria Rotundo M, Ciliberto D, Tomaino V, Fabiani F, Talarico D, Sperlongano P, Doldo P, Cannataro M, Caraglia M, Tassone P, Tagliaferri P. Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: A DMET microarray profiling study. *Cancer Biol Ther.* 2011 Nov 1;12(9):780-7. Epub 2011 Nov 1.
49. Correale P, Botta C, Cusi M, Del Vecchio M, De Santi M, Gori Savellini G, Bestoso E, Apollinari S, Mannucci S, Marra M, Abruzzese A, Aquino A, Turriziani M, Bonmassar L, Caraglia M, Tagliaferri P. Cetuximab +/- chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro. *Int J Cancer.* 2011 May 26. doi: 10.1002/ijc.26181.
50. Correale P, Botta C, Basile A, Pagliuchi M, Licchetta A, Martellucci I, Bestoso E, Apollinari S, Addeo R, Misso G, Romano O, Abruzzese A, Lamberti M, Luzzi L, Gotti G, Rotundo MS, Caraglia M, Tagliaferri P. Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients. *Cancer Biol Ther.* 2011 Jul 15;12(2):112-8. Epub 2011 Jul 15.
51. Di Martino MT, Arbitrio M, Guzzi PH, Leone E, Baudi F, Piro E, Prantera T, Cucinotto I, Calimeri T, Rossi M, Veltri P, Cannataro M, Tagliaferri P, Tassone P. A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling. *Br J Haematol.* 2011 Aug;154(4):529-33. doi:10.1111/j.1365-2141.2011.08622.x.

- 52.** Marra M, Salzano G, Leonetti C, Tassone P, Scarsella M, Zappavigna S, Calimeri T, Franco R, Liguori G, Cigliana G, Ascani R, La Rotonda MI, Abbruzzese A, Tagliaferri P, Caraglia M, De Rosa G. Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. *Nanomedicine*. 2011 Mar 29.
- 53.** Gori S, Di Maio M, Pinto C, Alabiso O, Baldini E, Beretta GD, Caffo O, Caroti C, Crinò L, De Laurentiis M, Dinota A, Di Vito F, Gebbia V, Giustini L, Graiff C, Guida M, Lelli G, Lombardo M, Muggiano A, Puglisi F, Romito S, Salvagno L, Tagliaferri P, Terzoli E, Venturini M. AIOM Working Group Interaction with Regional Sections (2007-2009). Differences in the availability of new anti-cancer drugs for Italian patients treated in different regions. Results of analysis conducted by the Italian Society Of Medical Oncology (AIOM). *Tumori* 2010 Nov-Dec;96(6):1010-5 .
- 54.** Calimeri T, Battista E, Conforti F, Neri P, Di Martino MT, Rossi M, Foresta U, Piro E, Ferrara F, Amorosi A, Bahlis N, Anderson KC, Munshi N, Tagliaferri P, Causa P, and Tassone P. A unique 3-D SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. *Leukemia*, 2011 Apr; 25(4):707-11. Epub 2011 Jan 14. PubMed PMID: 21233838; PubMed Central PMCID: PMC3089835. Correale P, Cusi MG, Tagliaferri P. Immunomodulatory properties of anticancer monoclonal antibodies: is the 'magic bullet' still a reliable paradigm? *Immunotherapy*. 2011 Jan;3(1):1-4. PubMed PMID: 21174549.
- 55.** Correale P, Remondo C, Carbone SF, Ricci V, Migali C, Martellucci I, Licchetta A, Addeo R, Volterrani L, Gotti G, Rotundo MS, Tassone P, Sperlongano P, Abbruzzese A, Caraglia M, Tagliaferri P, Francini G. Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients. *Cancer Biol Ther*. 2010 May;9(9):685-93.
- 56.** Palomba S, Falbo A, Del Negro S, Rocca M, Russo T, Cariati F, Annunziata G, Tolino A, Tagliaferri P, Zullo F. Ultra-conservative fertility-sparing strategy for bilateral borderline ovarian tumours: an 11-year follow-up. *Hum Reprod*. 2010 Aug;25(8):1966-72.
- 57.** Correale P, Marra M, Remondo C, Migali C, Misso G, Arcuri FP, Del Vecchio MT, Carducci A, Loiacono L, Tassone P, Abbruzzese A, Tagliaferri P, Caraglia M. Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC). *Eur J Cancer*. 2010 Apr 15.

58. Correale P, Rotundo MS, Del Vecchio MT, Remondo C, Migali C, Ginanneschi C, Tsang KY, Licchetta A, Mannucci S, Loiacono L, Tassone P, Francini G, Tagliaferri P. Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. *J Immunother*. 2010 May;33(4):435-41.
59. Tassone P, Tagliaferri P, Rossi M, Calimeri T, Bulotta A, Abbruzzese A, Caraglia M, Neri P. Challenging the current approaches to multiple myeloma-related bone disease: from bisphosphonates to target therapy. *Curr Cancer Drug Targets*. 2009 Nov;9(7):854-70. Review.
60. Marra M, Abbruzzese A, Addeo R, Del Prete S, Tassone P, Tonini G, Tagliaferri P, Santini D, Caraglia M. Cutting the limits of aminobisphosphonates: new strategies for the potentiation of their anti-tumour effects. *Curr Cancer Drug Targets*. 2009 Nov;9(7):791-800. Review.
61. Tagliaferri P, Ventura M, Baudi F, Cucinotto I, Arbitrio M, Di Martino MT, Tassone P. BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality? *J Ovarian Res*. 2009 Oct 13;2:14.
62. Blotta S, Tassone P, Prabhala RH, Tagliaferri P, Cervi D, Amin S, Jakubikova J, Tai YT, Podar K, Mitsiades CS, Zullo A, Franco B, Anderson KC, Munshi NC. Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. *Blood*. 2009 Oct 8;114(15):3276-84. Epub 2009 Jul 8. PubMed PMID:19587378; PubMed Central PMCID: PMC2759650.
63. Caraglia M, Marra M, Tagliaferri P, Lamberts SW, Zappavigna S, Misso G, Cavagnini F, Facchini G, Abbruzzese A, Hofland LJ, Vitale G. Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways. *Curr Cancer Drug Targets*. 2009 Aug;9(5):690-704. Epub 2009 Aug 1. Review..
64. Tassone P, Di Martino MT, Ventura M, Pietragalla A, Cucinotto I, Calimeri T, Bulotta A, Neri P, Caraglia M, Tagliaferri P. Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo. *Cancer Biol Ther*. 2009 Apr;8(7):648-53. Epub 2009 Apr 28.
65. Cosco D, Bulotta A, Ventura M, Celia C, Calimeri T, Perri G, Paolino D, Costa N, Neri P, Tagliaferri P, Tassone P, Fresta M. In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer. *Cancer Chemother Pharmacol*. 2009 Oct;64(5):1009-20. Epub 2009 Mar 5.

66. Correale P, Miano ST, Remondo C, Migali C, Rotundo MS, Macrì P, Tagliaferri P, Tassone P, Caraglia M, Gotti G, Francini G. Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte- macrophage colony stimulating factor and low dose aldesleukine. *Cancer Biol Ther.* 2009 Mar 9;8(6). [Epub ahead of print].
67. Zullo F, Palomba S, Falbo A, Russo T, Mocciaro R, Tartaglia E, Tagliaferri P, Mastrantonio P. Laparoscopic surgery vs laparotomy for early stage endometrial cancer: long-term data of a randomized controlled trial. *Am J Obstet Gynecol.* 2009 Mar;200(3):296.e1-9. Epub 2009 Jan 24.
68. Neri P, Tagliaferri P, Di Martino MT, Calimeri T, Amodio N, Bulotta A, Ventura M, Eramo PO, Viscomi C, Arbitrio M, Rossi M, Caraglia M, Munshi NC, Anderson KC, Tassone P. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. *Br J Haematol.* 2008 Nov;143(4):520-31.
69. Correale P, Tagliaferri P, Fioravanti A, Del Vecchio MT, Remondo C, Montagnani F, Rotundo MS, Ginanneschi C, Martellucci I, Francini E, Cusi MG, Tassone P, Francini G. Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial). *Clin Cancer Res.* 2008 Jul 1;14(13):4192-9.
70. Barbieri V, Tassone P, Tagliaferri P. The IASLC Lung Cancer Staging Project: revision proposal of pleural effusion and contralateral nodule staging. *J Thorac Oncol.* 2008 Mar;3(3):317; author reply 317-8.
71. Cascinu S, Berardi R, Salvagli S, Beretta GD, Catalano V, Pucci F, Sombrero A, Tagliaferri P, La bianca R, Scartozzi M, Crocicchio F, Mari E, Ardizzoni E. A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation. *Br J Cancer.* 2008 Jan 15;98 (1):71-6
72. Addeo R, Faiola V, Guarrasi R, Montella L, Vincenti B, Papasso E, Cennamo G, Rotundo MS, Tagliaferri P, Canaglia M, Del Prete S. Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer elderly women \geq 65 years of age *Cancer Chemother Pharmacol.* 2007 Oct 9.

73. Caraglia M, Marra M, Viscomi C, D'Alessandro AM, Budillon A, Meo G, Arra C, Barbieri A, Rapp UR, Baldi A, Tassone P, Venuta S, Abruzzese A, Tagliaferri P The Farnesyltransferase inhibitor R115777 (ZARNESTRA) enhances the pro-apoptotic activity of interferon-alpha through the inhibition of multiple survival pathways. *Int J Cancer* 2007 Nov. 15;121(10):2317-30
74. Amato R, Menniti M, Agosti V, Boito R, Costa N, Bond HM, Barbieri V, Tagliaferri P, Venuta S, Pernotti N. IL-2 signals through Sgk1 and inhibits proliferation and apoptosis in kidney cancer cells *J Mol Med.* 2007 Jul;85(7):707-21
75. Tassone P, Tagliaferri P, Cucinotto I, Lavecchia AM, Leone F, Pietragalla A, Salvino A, Barbieri V, Venuta S. Pegylated liposomal doxorubicin is active in Steward-Treves syndrome *Ann Oncol.* 2007 May;18(5):959-60
76. Lamberti A, Longo O, Marra M, Tagliaferri P, Bismuto E, Fiengo A., Viscomi C, Budillon A, Rapp UR, Wang E, Venuta S, Abbruzzese A, Arcari P and M. Caraglia. C-Raf antagonizes apoptosis induced by IFN- in human lung cancer cells by phosphorylation and increase of the intracellular content of Elongation Factor 1 *Cell Death Differ.* 2007 May;14(5):952-62
77. Tassone P, Tagliaferri P , Fulciniti MT, Di Martino MT and S Venuta. Novel Therapeutic Approaches Based on the Targeting of Microenvironment-Derived Survival Pathways in Human Cancer: Experimental Models and Translational Issue *Curr Pharm Des* 2007;13(5):487-96
78. Tassone P, Tagliaferri P, Rossi M, Gaspari M, Terracciano R, Venuta S. Genetics and molecular profiling of multiple myeloma: novel tools for clinical management? *Eur J Cancer.* 2006 Jul;42(11):1530-8. Epub 2006 Jul 3. 3.706
79. Caraglia M, Marra M, Meo G, Addeo SR, Tagliaferri P, Budillon A. EGF-R small inhibitors and anti-EGF-R antibodies: advantages and limits of a new avenue in anticancer therapy. *Recent Patents Anticancer Drug Discov.* 2006 Jun;1(2):209-22. Review.
80. Caraglia M, Tassone P, Marra M, Budillon A, Venuta S, Tagliaferri P. Targeting Raf-kinase: molecular rationales and translational issues. *Ann Oncol.* 2006 Jun;17(suppl 7):vii124-vii127.
81. Terracciano R, Gaspari M, Testa F, Pasqua L, Tagliaferri P, Cheng MM, Nijdam AJ, Petricoin EF, Liotta LA, Cuda G, Ferrari M, Venuta S. Selective binding and enrichment for low-molecular weight biomarker molecules in human plasma after exposure to nanoporous silica particles. *Proteomics.* 2006 Jun;6(11):3243-50.

- 82.** Valerio MR, Tagliaferri P, Raspagliesi F, Fulfaro F, Badalamenti G, Arcara C, Cicero G, Russo A, Venuta S, Guarneri G, Gebbia N. A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma. *Int J Gynecol Cancer*. 2006 Jan-Feb;16 Suppl 1:79-85.
- 83.** Bruzzese F, Di Gennaro E, Avallone A, Pepe S, Arra C, Caraglia M, Tagliaferri P, Budillon A. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo. *Clin Cancer Res*. 2006 Jan 15;12(2):617-25.
- 84.** Zullo F, Palomba S, Russo T, Falbo A, Costantino M, Tolino A, Zupi E, Tagliaferri P, Venuta S. A prospective randomized comparison between laparoscopic and laparotomic approaches in women with early stage endometrial cancer: a focus on the quality of life. *Am J Obstet Gynecol*. 2005 Oct;193(4):1344-52.
- 85.** Caraglia M, Addeo R, Costanzo R, Montella L, Faiola V, Marra M, Abruzzese A, Palmieri G, Budillon A, Grillone F, Venuta S, Tagliaferri P, Del Prete S. Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours. *Cancer Chemother Pharmacol*. 2006 Jan;57(1):34-9. Epub 2005 Nov 5.
- 86.** Tassone P, Neri P, Burger R, Savino R, Shamma M, Catley L, Podar K, Chauhan D, Masciari S, Gozzini A, Tagliaferri P, Venuta S, Munshi NC, Anderson KC. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. *Clin Cancer Res*. 2005 Jun 1;11(11):4251-8.
- 87.** Caraglia M, Budillon A, Tagliaferri P, Marra M, Abruzzese A, Caponigro F. Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications. *Curr Drug Targets*. 2005 May;6(3):301-23. Review.
- 88.** Tagliaferri P, Tassone P, Blotta S, Viscomi C, Grillone F, Budillon A, Caraglia M, Venuta S. Antitumor therapeutic strategies based on the targeting of epidermal growth factor-induced survival pathways. *Curr Drug Targets*. 2005 May;6(3):289-300. Review.
- 89.** Tassone P, Blotta S, Palmieri C, Masciari S, Quaresima B, Montagna M, D'Andrea E, Eramo OP, Migale L, Costanzo F, Tagliaferri P, Venuta S.
- 90.** Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents. *Int J Oncol*. 2005 May;26(5):1257-63.

- 91.75:** Tagliaferri P, Caraglia M, Budillon A, Marra M, Vitale G, Viscomi C, Masciari S, Tassone P, Abbruzzese A, Venuta S. New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-alpha) treatment of human cancer. *Cancer Immunol Immunother.* 2005 Jan;54(1):1-10. Review.
- 92.76:** Damiano R, D'Armiento M, Cantiello F, Amorosi A, Tagliaferri P, Sacco R, Venuta S. Gemcitabine and cisplatin following surgical treatment of urinary bladder carcinosarcoma. *Tumori.* 2004 Sep-Oct;90(5):458-60.
- 93.** Caraglia M, Vitale G, Marra M, Budillon A, Tagliaferri P, Abbruzzese A. Alpha-interferon and its effects on signalling pathways within cells. *Curr Protein Pept Sci.* 2004 Dec;5(6):475-85. Review.
- 94.** Caraglia M, D'Alessandro AM, Marra M, Giuberti G, Vitale G, Viscomi C, Colao A, Prete SD, Tagliaferri P, Tassone P, Budillon A, Venuta S, Abbruzzese A. The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate. *Oncogene.* 2004 Sep 9;23(41):6900-13.
- 95.** Caraglia M, Marra M, Giuberti G, D'Alessandro AM, Baldi A, Tassone P, Venuta S, Tagliaferri P, Abbruzzese A. The eukaryotic initiation factor 5A is involved in the regulation of proliferation and apoptosis induced by interferon-alpha and EGF in human cancer cells. *J Biochem (Tokyo).* 2003 Jun;133(6):757-65.
- 96.** Tassone P, Tagliaferri P, Viscomi C, Palmieri C, Caraglia M, D'Alessandro A, Galea E, Goel A, Abbruzzese A, Boland CR, Venuta S. Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. *Br J Cancer.* 2003 Jun 16;88(12):1971-8.
- 97.** Caraglia M, Tagliaferri P, Marra M, Giuberti G, Budillon A, Gennaro ED, Pepe S, Vitale G, Improta S, Tassone P, Venuta S, Bianco AR, Abbruzzese A. EGF activates an inducible survival response via the RAS-> Erk-1/2 pathway to counteract interferon-alpha-mediated apoptosis in epidermoid cancer cells. *Cell Death Differ.* 2003 Feb;10(2):218-29.
- 98.** Tassone P, Tagliaferri P, Perricelli A, Blotta S, Quaresima B, Martelli ML, Goel A, Barbieri V, Costanzo F, Boland CR, Venuta S. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC-1937 human breast cancer cells. *Br J Cancer.* 2003 Apr 22;88(8):1285-91.
- 99.** Pelaia G, Cuda G, Vatrella A, Fratto D, Grembiale RD, Tagliaferri P, Maselli R, Costanzo FS, Marsico SA. Effects of transforming growth factor-[beta] and budesonide on mitogen-activated protein kinase activation and apoptosis in

airway epithelial cells. *Am J Respir Cell Mol Biol.* 2003 Jul;29(1):12-8. Epub 2003 Jan 10.

- 100.** Tassone P, Galea E, Forciniti S, Tagliaferri P, Venuta S. The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells. *Int J Oncol.* 2002 Oct;21(4):867-73.
- 101.** Tassone P, Bonelli P, Tuccillo F, Bond HM, D'Armiento FP, Galea E, Calmieri C, Tagliaferri P, Natali PG, Venuta S. Differential expression of UN1, early thymocyte-associated sialoglycoprotein, in breast normal tissue, benign disease and carcinomas. *Anticancer Res.* 2002 Jul-Aug;22(4):2333-40.
- 102.** Pizzi C, Caraglia M, Cianciulli M, Fabbrocini A, Libroia A, Matano E, Contegiacomo A, Del Prete S, Abbruzzese A, Martignetti A, Tagliaferri P, Bianco AR. Low-dose recombinant IL-2 induces psychological changes: monitoring by Minnesota Multiphasic Personality Inventory (MMPI). *Anticancer Res.* 2002 Mar-Apr;22(2A):727-32.
- 103.** Tassone P, Tagliaferri P, Galea E, Palmieri C, Bonelli P, Martelli ML, Tuccillo F, Turco MC, Venuta S. Oxaliplatin (L-OHP) treatment of human myeloma cells induces in vitro growth inhibition and apoptotic cell death. *Eur J Cancer.* 2002 May;38(8):1141-7.
- 104.** Tassone P, Tuccillo F, Bonelli P, D'Armiento FP, Bond HM, Palmieri C, Tagliaferri P, Venuta S. Fetal ontogeny and tumor expression of the early thymic antigen UN1. *Int J Oncol.* 2002 Apr;20(4):707-11.
- 105.** Vitale G, Caraglia M, Ciccarelli A, Lupoli G, Abbruzzese A, Tagliaferri P, Lupoli G. Current approaches and perspectives in the therapy of medullary thyroid carcinoma. *Cancer.* 2001 May 1;91(9):1797-808.
- 106.** Cuda G, Gallelli A, Nistico A, Tassone P, Barbieri V, Tagliaferri P, Costanzo FS, Tranfa CM, Venuta S. Detection of microsatellite instability and loss of heterozygosity in serum DNA of small and non-small cell lung cancer patients: a tool for early diagnosis? *Lung Cancer.* 2000 Dec;30(3):211-4.
- 107.** Caraglia M, Budillon A, Vitale G, Lupoli G, Tagliaferri P, Abbruzzese A. Modulation of molecular mechanisms involved in protein synthesis machinery as a new tool for the control of cell proliferation. *Eur J Biochem.* 2000 Jul;267(13):3919-36. Review.
- 108.** Tassone P, Forciniti S, Galea E, Savino R, Turco MC, Iacopino P, Tagliaferri P, Morrone G, Ciliberto G, Venuta S. Synergistic induction of growth arrest and apoptosis of human myeloma cells by the IL-6 super-antagonist Sant7 and Dexamethasone. *Cell Death Differ.* 2000 Mar;7(3):327-8.

109. Matano E, Tagliaferri P, Libroia A, Damiano V, Fabbrocini A, De Lorenzo S, Bianco AR. Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented phase II study. *Br J Cancer*. 2000 Jun;82(11):1772-5.
110. Tassone P, Forciniti S, Galea E, Morrone G, Turco MC, Martinelli V, Tagliaferri P, Venuta S. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. *Leukemia*. 2000 May;14(5):841-4.
111. Caraglia M, Tagliaferri P, Budillon A, Abbruzzese A. Post-translational modifications of eukaryotic initiation factor-5A (eIF-5A) as a new target for anti-cancer therapy. *Adv Exp Med Biol*. 1999;472:187-98.
112. Vitale G, Tagliaferri P, Caraglia M, Rampone E, Ciccarelli A, Bianco AR, Abbruzzese A, Lupoli G. Slow release lanreotide in combination with interferon-alpha2b in the treatment of symptomatic advanced medullary thyroid carcinoma. *J Clin Endocrinol Metab*. 2000 Mar;85(3):983-8.
113. Budillon A, Di Gennaro E, Caraglia M, Barbarulo D, Abbruzzese A, Tagliaferri P. 8-Cl-cAMP antagonizes mitogen-activated protein kinase activation and cell growth stimulation induced by epidermal growth factor. *Br J Cancer*. 1999 Dec;81(7):1134-41.
114. Caraglia M, Abbruzzese A, Leardi A, Pepe S, Budillon A, Baldassare G, Selleri C, Lorenzo SD, Fabbrocini A, Giuberti G, Vitale G, Lupoli G, Bianco AR, Tagliaferri P. Interferon-alpha induces apoptosis in human KB cells through a stress-dependent mitogen activated protein kinase pathway that is antagonized by epidermal growth factor. *Cell Death Differ*. 1999 Aug;6(8):773-80.
115. Caraglia M, Di Gennaro E, Barbarulo D, Marra M, Tagliaferri P, Abbruzzese A, Budillon A. Up-regulated EGF receptors undergo to rapid internalization and ubiquitin-dependent degradation in human cancer cells exposed to 8-Cl-cAMP. *FEBS Lett*. 1999 Mar 26;447(2-3):203-8.
116. Lupoli G, Vitale G, Caraglia M, Fittipaldi MR, Abbruzzese A, Tagliaferri P, Bianco AR. Familial papillary thyroid microcarcinoma: a new clinical entity. *Lancet*. 1999 Feb 20;353(9153):637-9.
117. Caraglia M, Tagliaferri P, Budillon A, Abbruzzese A. Post translational modifications of eukaryotic Initiation Factor-5A (eIF-5A) as a new target for anticancer therapy *Advances in Nutrition and cancer 2* Kluwer Academic, edited by Zappia et al 1999 pp 187-197

118. Beninati S, Gentile V, Caraglia M, Lentini A, Tagliaferri P, Abbruzzese A. Tissue transglutaminase expression affects hypusine metabolism in BALB/c 3T3 cells. *FEBS Lett.* 1998 Oct 16;437(1-2):34-8.
119. Leardi A, Caraglia M, Selleri C, Pepe S, Pizzi C, Notaro R, Fabbrocini A, De Lorenzo S, Musico M, Abbruzzese A, Bianco AR, Tagliaferri P. Desferioxamine increases iron depletion and apoptosis induced by ara-C of human myeloid leukaemic cells. *Br J Haematol.* 1998 Aug;102(3):746-52.
120. Palmieri G, Morabito A, Rea A, Biondi E, Lauria R, Matano E, Pagliarulo C, Montesarchio V, Tagliaferri P, Bianco AR. Tailored therapy for aggressive non-Hodgkin's lymphoma: results of a phase II study with a long-term follow-up. *Int J Oncol.* 1998 Jul;13(1):121-7.
121. Tagliaferri P, Guarrasi R, Caraglia M, Morelli D, Fabbrocini A, Correale P, Bianco AR. Tumour cell resistance to non-MHC-restricted lymphocytes: molecular mechanisms and clinical implications. *Cancer Immunol Immunother.* 1998 May;46(3):121-7. Review. No abstract available.
122. Tagliaferri P, Barile C, Caraglia M, Guarrasi R, Morelli D, Ricciardi B, Martignetti A, Librera MT, Matano E, Della Vecchia A, Catalano G, Famiani M, Palmieri G, Correale P, Bianco AR. Daily low-dose subcutaneous recombinant interleukin-2 by alternate weekly administration: antitumor activity and immunomodulatory effects. *Am J Clin Oncol.* 1998 Feb;21(1):48-53.
123. Caraglia M, Leardi AI, Improta S, Perin V, Ricciardi B, Arra C, Ferraro P, Fabbrocini A, Pinto A, Bianco AR, Tagliaferri P. Transient exposure to cytarabine increases peptide growth factor receptor expression and tumorigenicity of melanoma cells. *Anticancer Res.* 1997 Jul-Aug;17(4A):2369-75.
124. Caraglia M, Passeggio A, Beninati S, Leardi A, Nicolini L, Improta S, Pinto A, Bianco AR, Tagliaferri P, Abbruzzese A. Interferon alpha2 recombinant and epidermal growth factor modulate proliferation and hypusine synthesis in human epidermoid cancer KB cells. *Biochem J.* 1997 Jun 15;324 (Pt 3):737-41.
125. Correale P, Tagliaferri P, Guarrasi R, Caraglia M, Giuliano M, Martinetti MR, Bianco AR, Procopio A. Extracellular adenosine 5' triphosphate involvement in the death of LAK-engaged human tumor cells via P2X-receptor activation. *Immunol Lett.* 1997 Feb;55(2):69-78.
126. Tagliaferri P, Correale P, Mottola M, de Simone G, Montesarchio V, Matano E, Rea A, Morabito A, Famiani M, Ciardiello F, Tortora G, Caraglia M, Barile C, Palmieri G, Bianco AR. High-dose recombinant interleukin-

2/verapamil combination in advanced cancer. *Eur J Cancer*. 1996 Jul;32A(8):1436-7.

- 127.** Tagliaferri P, Tortora G, Guarrasi R, Damiano V, Ruggiero A, Morelli D, Caraglia M, Bianco R, di Isernia G, Pepe S, Arteaga CL, Langton-Webster BC, Bianco AR, Ciardiello F. Differential sensitivity to non-major histocompatibility complex-restricted recombinant interleukin 2-activated lymphocyte killing of human mammary epithelial MCF-10A cells overexpressing oncogenes or protein kinase A subunits. *Clin Cancer Res*. 1996 Jan;2(1):207-14.
- 128.** Caraglia M, Leardi A, Corradino S, Ciardiello F, Budillon A, Guarrasi R, Bianco AR, Tagliaferri P. alpha-Interferon potentiates epidermal growth factor receptor-mediated effects on human epidermoid carcinoma KB cells. *Int J Cancer*. 1995 May 4;61(3):342-7.
- 129.** Tortora G, Ciardiello F, Pepe S, Tagliaferri P, Ruggiero A, Bianco C, Guarrasi R, Miki K, Bianco AR. Phase I clinical study with 8-chloro-cAMP and evaluation of immunological effects in cancer patients *Clin Cancer Res*. 1995 Apr;1(4):377-84.
- 130.** Correale P, Caraglia M, Fabbrocini A, Guarrasi R, Pepe S, Patella V, Marone G, Pinto A, Bianco AR, Tagliaferri P. Bryostatins 1 enhances lymphokine activated killer sensitivity and modulates the beta 1 integrin profile of cultured human tumor cells. *Anticancer Drugs*. 1995 Apr;6(2):285-90.
- 131.** Iaffaioli RV, Frasci G, Palmieri G, Tagliaferri P, Montesarchio V, Pagliarulo C, Tortoriello A, Facchini G, Matano E, Lauria R, et al. Chlorambucil, vincristine and cytarabine (COA) treatment of low grade lymphomas. *Leuk Lymphoma*. 1995 Mar;17(1-2):147-53.
- 132.** Ciardiello F, Damiano V, Bianco C, di Isernia G, Ruggiero A, Caraglia M, Tagliaferri P, Baselga J, Mendelsohn J, Bianco AR, et al. Cooperative antiproliferative effects of 8-chloro-cyclic AMP and 528 anti-epidermal growth factor receptor monoclonal antibody on human cancer cells. *Clin Cancer Res*. 1995 Feb;1(2):161-7.
- 133.** Tagliaferri P, Matano E, Rea A, Famiani M, Ciardiello F, Tortora G, Montesarchio V, Morabito A, Caraglia M, De Laurentiis, De Placido S, Palmieri G, Bianco AR Mitoxantrone, etoposide and Bleomycin (MEB) chemotherapy in non-Hodkin's lymphoma patients non eligible for standard cyclophosphamide, doxorubicin vincristine and prednisone (CHOP) combination *Oncology Reports* 1995 2:365-368, 1995
- 134.** Palmieri G, Morabito A, Rea A, Caraglia M, Tagliaferri P, Bianco AR. Cytosine arabinoside (Ara-C) plus alpha-interferon (alpha IFN) determine

- prolonged complete remissions in patients with aggressive non-Hodgkin's lymphoma partially responsive to first-line doxorubicin-containing regimens. *Br J Haematol.* 1994 Oct;88(2):421-3.
- 135.** Caraglia M, Libroia AM, Corradino S, Coppola V, Guarrasi R, Barile C, Genua G, Bianco AR, Tagliaferri P. Alpha-interferon induces depletion of intracellular iron content and upregulation of functional transferrin receptors on human epidermoid cancer KB cells. *Biochem Biophys Res Commun.* 1994 Aug 30;203(1):281-8.
- 136.** Tagliaferri P, Caraglia M, Muraro R, Pinto A, Budillon A, Zagonel V, Bianco AR. Pharmacological modulation of peptide growth factor receptor expression on tumor cells as a basis for cancer therapy. *Anticancer Drugs.* 1994 Aug;5(4):379-93. Review.
- 137.** Caraglia M, Pinto A, Correale P, Zagonel V, Genua G, Leardi A, Pepe S, Bianco AR, Tagliaferri P. 5-Aza-2'-deoxycytidine induces growth inhibition and upregulation of epidermal growth factor receptor on human epithelial cancer cells. *Ann Oncol.* 1994 Mar;5(3):269-76.
- 138.** Correale P., Caraglia M, Pepe S, Ricciardi B, Barile C, Montagnani S, Pacelli R, Bianco AR, Tagliaferri P Phorbol-12-myristate 13-acetate (PMA) induces neuroendocrine differentiation and reverses doxorubicin resistance of human colon carcinoma cells in vitro *International J Oncol* 1994 4:423-27
- 139.** Tagliaferri P, Correale P, Mottola M, de Simone G, Rea A, Ascione A, Morabito A, Matano E, Montesarchio V, Canaglia M, Tortora G, Ciardiello F, Barile C, Palmieri G, Bianco AR Cardiovascular monitoring of drug-resistant lymphoma patients treated with EPOCH chemotherapy plus high dose verapamil in continuous infusion *Oncology Rep* 1994 1:341-44
- 140.** Caraglia M, Tagliaferri P, Correale P, Genua G, Pinto A, Del Vecchio S, Esposito G, Bianco AR. Cytosine arabinoside increases the binding of 125I-labelled epidermal growth factor and 125I-transferrin and enhances the in vitro targeting of human tumour cells with anti-(growth factor receptor) mAb. *Cancer Immunol Immunother.* 1993 Aug;37(3):150-6.
- 141.** Correale P, Tagliaferri P, Camera A, Caraglia M, Del Vecchio L, De Laurentiis M, Pinto A, Rotoli B, Bianco AR. CD10/common acute lymphoblastic leukemia-associated antigen and adhesion factor expression is predictive for lymphokine-activated killing sensitivity of adult B-lineage acute lymphoblastic leukemia.
- 142.** Correale P, Procopio A, Celio L, Caraglia m, Genua G, Coppola V, Pepe S, Normanno N, Vecchio I, Calmieri G, Montagnani S, Tagliaferri P, Bianco AR Phorbol 12-Myristate 13-Acetate induces resistance of human melanoma

cells to natural killer and lymphokine activated killer mediated cytotoxicity
Cancer immunol immunother 34:272-278, 1992

143. Scala S, Pacelli R, Iaffaioli RV, Normanno N, Pepe S, Frasci G, Genua G, Tsuruo T, Tagliaferri P, Bianco AR. Reversal of adriamycin resistance by recombinant alpha-interferon in multidrug-resistant human colon carcinoma LoVo-doxorubicin cells. *Cancer Res.* 1991 Sep 15;51(18):4898-902.
144. Budillon A, Tagliaferri P, Caraglia M, Torrasi MR, Normanno N, Iacobelli S, Palmieri G, Stoppelli MP, Frati L, Bianco AR. Upregulation of epidermal growth factor receptor induced by alpha-interferon in human epidermoid cancer cells. *Cancer Res.* 1991 Feb 15;51(4):1294-9.
145. Correale P, Tagliaferri P, Celio L, Genua G, Montagnani S, Bianco AR. Verapamil upregulates sensitivity of human colon and breast cancer cells to LAK-cytotoxicity in vitro. *Eur J Cancer.* 1991;27(11):1393-5.
146. Palmieri G, Tagliaferri P, Contegiacomo A, Caponigro F, Iaffaioli RV, Calderopoli R, Lauria R, Montesarchio V, Bianco AR. Changing presentation in non-Hodgkin lymphoma. *Lancet.* 1990 May 19;335(8699):1221. No abstract available.
147. D'Agostino L, Pignata S, Daniele B, D'Adamo G, Ferraro C, Silvestro G, Tagliaferri P, Contegiacomo A, Gentile R, Tritto G, et al. Polyamine uptake by human colon carcinoma cell line CaCo-2. *Digestion.* 1990;46 Suppl 2:352-9. 1.826
148. Calderopoli R, Pepe S, Tagliaferri P, Tortora G, Contegiacomo A, Peluso G, Metafora S, Cho-Chung YS, Bianco AR. Control of monocytic cell growth and HLA-Dr expression by alpha-interferon and cAMP analogues. *Biochemical aspects of the immunopathology of reproduction* 139-143, *Acta Medica* 1989
149. D'Agostino L, Daniele B, Pignata S, Gentile R, Tagliaferri P, Contegiacomo A, Silvestro G, Polistina C, Bianco AR, Mazzacca G. Ornithine decarboxylase and diamine oxidase in human colon carcinoma cell line CaCo-2 in culture. *Gastroenterology.* 1989 Oct;97(4):888-94.
150. Tortora G, Clair T, Katsaros D, Ally S, Colamonicis O, Neckers LM, Tagliaferri P, Jahnsen T, Robins RK, Cho-Chung YS. Induction of megakaryocytic differentiation and modulation of protein kinase gene expression by site-selective cAMP analogs in K-562 human leukemic cells. *Proc Natl Acad Sci U S A.* 1989 Apr;86(8):2849-52.

- 151.** Talbot N, Tagliaferri P, Yanagihara K, Rhim JS, Bassin RH, Benade LEA pH dependent differential cytotoxicity of ouabain for human cells transformed by certain oncogenes. *Oncogene* 1988 3: 23-2
- 152.** **137:** Cho-Chung YS, Clair T, Tagliaferri P, Ally S, Katsaros D, Tortora G, Neckers L, Avery TL, Crabtree GW, Robins RK. Site-selective cyclic AMP analogs as new biological tools in growth control, differentiation, and proto-oncogene regulation. *Cancer Invest.* 1989;7(2):161-77. Review.
- 153.** Tagliaferri P, Katsaros D, Clair T, Ally S, Tortora G, Neckers L, Rubalcava B, Parandoosh Z, Chang YA, Revankar GR, et al. Synergistic inhibition of growth of breast and colon human cancer cell lines by site-selective cyclic AMP analogs. *Cancer Res.* 1988 Mar 15;48(6):1642-50.
- 154.** Tagliaferri P, Katsaros D, Clair T, Neckers L, Robins RK, Cho-Chung YS. Reverse transformation of Harvey murine sarcoma virus-transformed NIH/3T3 cells by site-selective cyclic AMP analogs. *J Biol Chem.* 1988 Jan 5;263(1):409-16.
- 155.** Tortora G, Tagliaferri P, Clair T, Colamonici O, Neckers LM, Robins RK, Cho-Chung YS. Site-selective cAMP analogs at micromolar concentrations induce growth arrest and differentiation of acute promyelocytic, chronic myelocytic, and acute lymphocytic human leukemia cell lines. *Blood.* 1988 Jan;71(1):230-3.
- 156.** Clair T, Ally S, Tagliaferri P, Robins RK, Cho-Chung YS. Site-selective cAMP analogs induce nuclear translocation of the RII cAMP receptor protein in Ha-MuSV-transformed NIH/3T3 cells. *FEBS Lett.* 1987 Nov 30;224(2):377-84.
- 157.** Tagliaferri P, Yanagihara K, Ciardiello F, Talbot N, Flatow U, Benade L, Bassin RH. Effects of ouabain on NIH/3T3 cells transformed with retroviral oncogenes and on human tumor cell lines. *Int J Cancer.* 1987 Nov 15;40(5):653-8.
- 158.** Katsaros D, Tortora G, Tagliaferri P, Clair T, Ally S, Neckers L, Robins RK, Cho-Chung YS. Site-selective cyclic AMP analogs provide a new approach in the control of cancer cell growth. *FEBS Lett.* 1987 Oct 19;223(1):97-103.
- 159.** Benade LE, Talbot N, Tagliaferri P, Hardy C, Card J, Noda M, Najam N, Bassin RH. Ouabain sensitivity is linked to ras -transformation in human HOS cells. *Biochem Biophys Res Commun.* 1986 Apr 29;136(2):807-14.
- 160.** Tagliaferri P, Clair T, DeBortoli ME, Cho-Chung YS. Two classes of cAMP analogs synergistically inhibit p21 ras protein synthesis and phenotypic

transformation of NIH/3T3 cells transfected with Ha-MuSV DNA. *Biochem Biophys Res Commun.* 1985 Aug 15;130(3):1193-200.

Studi clinici in cui risulta PI

- Studio di Fase III, multicentrico, randomizzato, con LDK378 per via orale versus chemioterapia standard in pazienti adulti precedentemente con trattati con carcinoma polmonare non a piccole cellule non squamoso con arrangiamento di ALK(ALK positivo), in studio IIIB o IV. Studio interventistico.
- Studio multicentrico, randomizzato, in doppio- cieco, di fase III volto a valutare l'efficacia e la sicurezza di BIBF 1120 in combinazione con carboplatino e paclitaxel verso placebo più carboplatino e paclitaxel in pazienti con cancro ovarico avanzato BI1199.15 (LUME-OVAR 1)/ AGOOVAR12.
- Clinical protocol phase 3, randomized, open-label study of the efficacy and safety of crizotinib versus pemetrexed/cisplatin or pemetrexed/carboplatin in previously untreated patients with non-squamous carcinoma of the lung harboring a translocation or in version event involving the anaplastic lymphoma kinase (alk) gene locus”.
- An open-label, multi-center, expanded access study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer who have progressed following prior endocrine therapy, investigating the treatment of everolimus (RAD001) in combination with exemestane.
- Studio OGX-0011—11 (Synergy) Eudract n.2010-021011-16.
- Studio SAIL Eudract n. 2005-005887-97.
- Studio di fase III Multicentrico, randomizzato in aperto con Erlotinib (Tarceva) verso Chemioterapia, in pazienti con Carcinoma del polmone non a piccole cellule avanzato, i quali presentano una mutazione della Tirosin Kinasi nel dominio del fattore di crescita epidermoidale (EGFR).